文献速递呼吸道感染

机械通气COVID-19患者中COVID-19相关肺曲霉病:英国前瞻性多中心研究

COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study.
PubMed 文献 · Thorax · 2023-12-15

该研究在2020年3月至2021年3月纳入英国5个ICU的266例机械通气COVID-19成人患者,前瞻性评估CAPA的发病率、危险因素和死亡率。与 probable CAPA 相关的因素包括入ICU前28天内累计激素剂量、使用IL-6抑制剂和合并COPD。调整混杂因素后CAPA与90天死亡率的风险比无统计学显著性。

要点

  • 机械通气COVID-19患者中 probable CAPA 发生率为10.9%,中位诊断时间为入ICU后9天。
  • 入ICU前28天累计激素剂量、使用IL-6抑制剂及合并COPD与 probable CAPA 相关。
  • 调整混杂因素后CAPA与90天死亡率无显著独立关联。

核心结论

  • 在英国机械通气COVID-19患者中,probable CAPA与激素使用、IL-6抑制剂及既往COPD相关。
  • 调整预后变量后,CAPA未显示对死亡率有独立影响。

研究设计与样本

  • 前瞻性、多中心英国队列研究,纳入2020年3月至2021年3月5个ICU的266例机械通气COVID-19成人患者。
  • CAPA定义采用欧洲医学真菌学联盟和国际人类与动物真菌学学会标准,并对呼吸道和血清样本进行真菌检测。

主要发现

  • probable CAPA诊断中位时间为入ICU后9天(IQR 7-16)。
  • 多因素logistic回归显示,入ICU前28天内累计激素剂量(每100 mg泼尼松龙当量,aOR 1.16;95%CI 1.01-1.43)、使用IL-6抑制剂(aOR 2.79;95%CI 1.22-6.48)和COPD(aOR 4.78;95%CI 1.13-18.13)与 probable CAPA 相关。
  • probable CAPA患者死亡率为55%,无CAPA患者为46%;调整 immortal time bias 后CAPA与90天死亡率风险增加相关(HR 1.85;95%CI 1.07-3.19)。
  • 进一步调整混杂因素后,CAPA与90天死亡率的关联无统计学显著性(adjusted HR 1.57;95%CI 0.88-2.80)。

关键数值与推荐

  • CAPA定义采用欧洲医学真菌学联盟和国际人类与动物真菌学学会标准。
  • probable CAPA诊断中位时间为入ICU后9天(IQR 7-16)。

临床怎么用

  • 对机械通气COVID-19患者,尤其使用激素、IL-6抑制剂或合并COPD者,应警惕CAPA可能。
  • CAPA诊断需结合真菌学检测,本研究中 probable CAPA 中位诊断时间为入ICU后9天。
  • 抗真菌治疗与未治疗者死亡率无显著差异,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive pulmonary aspergillosis is a complication of severe COVID-19, with regional variation in reported incidence and mortality. We describe the incidence, risk factors and mortality associated with COVID-19-associated pulmonary aspergillosis (CAPA) in a prospective, multicentre UK cohort. METHODS: From March 2020 to March 2021, 266 mechanically ventilated adults with COVID-19 were enrolled across 5 UK hospital intensive care units (ICUs). CAPA was defined using European Confederation for Medical Mycology and the International Society for Human and Animal Mycology criteria and fungal diagnostics performed on respiratory and serum samples. RESULTS: Twenty-nine of 266 patients (10.9%) had probable CAPA, 14 (5.2%) possible CAPA and none proven CAPA. Probable CAPA was diagnosed a median of 9 (IQR 7-16) days after ICU admission. Factors associated with probable CAPA after multivariable logistic regression were cumulative steroid dose given within 28 days prior to ICU admission (adjusted OR (aOR) 1.16; 95% CI 1.01 to 1.43 per 100 mg prednisolone-equivalent), receipt of an interleukin (IL)-6 inhibitor (aOR 2.79; 95% CI 1.22 to 6.48) and chronic obstructive pulmonary disease (COPD) (aOR 4.78; 95% CI 1.13 to 18.13). Mortality in patients with probable CAPA was 55%, vs 46% in those without. After adjustment for immortal time bias, CAPA was associated with an increased risk of 90-day mortality (HR 1.85; 95% CI 1.07 to 3.19); however, this association did not remain statistically significant after further adjustment for confounders (adjusted HR 1.57; 95% CI 0.88 to 2.80). There was no difference in mortality between patients with CAPA prescribed antifungals (9 of 17; 53%) and those who were not (7 of 12; 58%) (p=0.77). INTERPRETATION: In this first prospective UK study, probable CAPA was associated with corticosteroid use, receipt of IL-6 inhibitors and pre-existing COPD. CAPA did not impact mortality following adjustment for prognostic variables.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Hurt W, Youngs J, Ball J, et al. COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study. Thorax. 2023. PMID: 37657925. doi:10.1136/thorax-2023-220002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。